EFM
COGT icon

E Fund Management’s Cogent Biosciences COGT Stock Holding History

E Fund Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$500K Sell
12,928
-3,176
-20% -$111K 0.01% 264
2026
Q1 		$620K Buy
+16,104
New +$595K 0.02% 238
2025
Q2 		$73.3K Sell
10,205
-5,465
-35% -$30.3K ﹤0.01% 382
2025
Q1 		$93.9K Buy
15,670
+4,290
+38% +$33.6K ﹤0.01% 384
2024
Q4 		$88.8K Buy
+11,380
New +$113K ﹤0.01% 381
2024
Q3 		– Sell
-11,173
Closed -$94.2K – 359
2024
Q2 		$94.2K Sell
11,173
-22,135
-66% -$168K 0.01% 305
2024
Q1 		$224K Buy
33,308
+17,897
+116% +$111K 0.01% 324
2023
Q4 		$90.6K Buy
+15,411
New +$118K 0.01% 304
2023
Q3 		– Sell
-11,088
Closed -$131K – 299
2023
Q2 		$131K Sell
11,088
-2,661
-19% -$30.5K 0.01% 292
2023
Q1 		$148K Sell
13,749
-3,226
-19% -$41.3K 0.01% 311
2022
Q4 		$196K Buy
16,975
+2,585
+18% +$32K 0.02% 306
2022
Q3 		$215K Buy
+14,390
New +$197K 0.02% 294

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

E Fund Management's COGT Position: Q2 2026 in Review

E Fund Management reduced its Cogent Biosciences (COGT) stake by 20% in Q2 2026, selling an estimated $111K and leaving 12,928 shares worth $500K. The position accounts for 0.01% of the portfolio, ranked #264.

E Fund Management first reported a position in COGT in Q3 2022 and has held it in 12 quarters since. The position peaked at $620K in Q1 2026. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • E Fund Management held 12,928 shares of Cogent Biosciences worth $500K as of Q2 2026.
  • E Fund Management sold 3,176 Cogent Biosciences shares in Q2 2026, an estimated $111K.
  • Cogent Biosciences made up 0.01% of E Fund Management's portfolio in Q2 2026, its #264 holding.
  • E Fund Management first reported a position in Cogent Biosciences in Q3 2022 and has held it in 12 quarters since.
  • E Fund Management's Cogent Biosciences position peaked at $620K in Q1 2026.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.